| Frank Wayne Mayhew, | |
|
1805 S Wood Dr, Okmulgee, OK 74447-6825 | |
| (918) 756-9250 | |
| Not Available |
| Full Name | Frank Wayne Mayhew |
|---|---|
| Gender | Male |
| Speciality | Counselor - Mental Health |
| Location | 1805 S Wood Dr, Okmulgee, Oklahoma |
| Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1003542838 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 101YM0800X | Counselor - Mental Health | (* (Not Available)) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Frank Wayne Mayhew, 802 W Broadway St, Henryetta, OK 74437-5076 Ph: (539) 600-8673 | Frank Wayne Mayhew, 1805 S Wood Dr, Okmulgee, OK 74447-6825 Ph: (918) 756-9250 |
News Archive
Naldemedine, an investigational peripherally acting mu-opioid receptor antagonist (PAMORA) under development by Shionogi & Co., Ltd., met its primary and secondary endpoints in a phase III study (COMPOSE I) for the treatment of opioid-induced constipation (OIC) in adult patients with chronic non-cancer pain receiving opioid therapy.
Public Health England (PHE) is cheering about a significant fall in the number of antibiotic prescriptions in England over the five years between 2014 and 2019, when it has dropped by 17%. However, with more and more bacterial infections showing antibiotic resistance every single year, there is no room for complacency.
Paola Leone, PhD, the director of the Cell and Gene Therapy Center and a professor of Cell Biology at the Rowan University School of Osteopathic Medicine, has been awarded a three-year, $477,000 grant from the National Institute of Neurological Disorders and Stroke to develop a stem cell-based therapy for Canavan disease, a rare but devastating neurological disorder in children that typically takes a child's life by age 10.
The U.S. Food and Drug Administration today approved Rituxan (rituximab), in combination with glucocorticoids (steroids), to treat patients with Wegener's granulomatosis (WG) and microscopic polyangiitis (MPA), two rare disorders that cause blood vessel inflammation (vasculitis).
EnzymeRx, LLC, a clinical-stage biotechnology company, announced top line results from its first clinical trial of pegsitacase (formerly called Uricase‑PEG 20). Pegsitacase is a pegylated uricase being developed by EnzymeRx for the treatment of refractory gout and for the management of hyperuricemia associated with tumor lysis syndrome.
› Verified 8 days ago
Leslie Lynn Crow, LPC Counselor Medicare: Not Enrolled in Medicare Practice Location: 100 W 7th St, Suite 102, Okmulgee, OK 74447 Phone: 918-758-1910 Fax: 918-756-1270 | |
Mrs. Naomi Hankins, Counselor Medicare: Not Enrolled in Medicare Practice Location: 1803 S Wood Dr, Okmulgee, OK 74447 Phone: 918-756-9250 | |
Miss Gay Lynn Peterson, Counselor Medicare: Not Enrolled in Medicare Practice Location: 323 W 6th St, Okmulgee, OK 74447 Phone: 918-756-9250 | |
Mrs. Thomasine L. Fife, LADC Counselor Medicare: Not Enrolled in Medicare Practice Location: 100 W 7th St Ste 102, Okmulgee, OK 74447 Phone: 918-758-1930 | |
Hilary Megan Snyder, MASTER OF ARTS IN CH Counselor Medicare: Not Enrolled in Medicare Practice Location: 1950 N Okmulgee, Okmulgee, OK 74447 Phone: 918-756-7700 Fax: 918-756-3347 | |
Ladonna Kay Shadlow, CBHCM, BA Counselor Medicare: Not Enrolled in Medicare Practice Location: 114 N Grand Ave Ste 418, Okmulgee, OK 74447 Phone: 918-227-2016 |